Advertisement

ADXS-HPV grated orphan drug designation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted orphan drug designation to ADXS-HPV for the treatment of stage II-IV invasive cervical cancer. ADXS-HPV is an immunotherapy drug candidate, developed by Advaxis Inc., which is designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for the transformation of infected cells into...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Advertisement
Advertisement